Is Eiko Lifescience overvalued or undervalued?

As of 27 June 2025, Eiko Lifescience has moved from a fair to an expensive valuation grade. The company appears to be overvalued based on its current financial metrics. Key ratios include a PE ratio of 46.97, an EV to EBITDA of 35.01, and a PEG ratio of 0.70, which suggests that the stock may not justify its high price given its earnings growth potential.
In comparison to its peers, Eiko Lifescience's PE ratio significantly exceeds that of Life Insurance, which stands at 12.53, indicating a stark valuation disparity. Additionally, Bajaj Finance, categorized as very expensive, has a PE of 35.35, further emphasizing Eiko's elevated valuation. Despite a recent stock return of 2.07% over the past week, the year-to-date return of -19.13% highlights the challenges the company faces relative to the Sensex's 7.58% gain. Overall, Eiko Lifescience is deemed overvalued in the current market context.